← All trials
NCT06077422
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2024
- Primary completion
- Jan 2, 2025
- Completion date
- Apr 5, 2025
- First posted
- Oct 11, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rutgers UniversityLead sponsor
- Pacira PharmaceuticalsCollaborator
- Rutgers UniversityReponsible party - principal investigator
- Rutgers UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.